KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. have formed a strategic alliance in a bid to offer comprehensive drug substance and drug product manufacturing solutions. The collaboration is set to expedite development timelines and provide scalable manufacturing capacities for biopharmaceutical organizations.
Acceleration of Drug Development and Manufacturing
This partnership between KBI Biopharma and Argonaut Manufacturing Services is designed to address crucial challenges in drug development and manufacturing. It aims to enhance the alignment and integration between development and production processes, thereby enabling biopharmaceutical companies to smoothly transition from development to full-scale manufacturing.
Expertise and Technology: A Powerful Combination
KBI Biopharma brings to the table its proficiency in innovative biopharmaceutical development. Argonaut, on the other hand, offers cutting-edge technologies in drug product manufacturing. Both leaders, J.D. Mowery of KBI and Wayne Woodard of Argonaut, highlighted the alignment of their companies’ values and vision. They emphasized that this partnership will provide an integrated solution that will benefit biopharmaceutical organizations.
Expansion of Manufacturing Capacities
Argonaut has also announced a capital investment for the expansion of its manufacturing facilities in Carlsbad, CA. This move shows Argonaut’s commitment to growth and increased manufacturing capacity. As an FDA-registered cGMP contract manufacturing organization, Argonaut provides services including aseptic drug fill/finish, diagnostic manufacturing with lyophilization technology, and comprehensive analytical quality control services. These services cater to the life science industry, molecular diagnostics, and the biopharma sector.
Both KBI Biopharma and Argonaut Manufacturing Services are committed to supporting customers in bringing clinical and commercial therapies to patients quickly, safely, and efficiently. This collaboration is a testament to their shared vision and the mutual goal of transforming the landscape of biopharmaceutical development and manufacturing.
